• Welcome, Guest. Please login or register.
    May 31, 2020, 11:59:07 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:


Click to visit us on Facebook

If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Thalassemia Patients and Friends and thalpal Ā© A. Battaglia 2019

55292 Posts in 5909 Topics by 6204 Members
Latest Member: pareshdas1985

Forum Tip: 
You can now simply type thalpal.com into your browser and it will take you to this site. Tell your friends about this easy-to-remember name.
« previous next »
Pages: 1 Go Down Print
Author Topic: Current status of globin gene therapy for the treatment of beta-thalassaemia  (Read 3419 times)
Andy Battaglia
Supreme Member
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8656

Will thal rule you or will you rule thal?

« on: August 25, 2008, 09:29:35 AM »

This article was published in May, 2008


Br J Haematol. 2008 May ;141 (3):335-45 18410569 (P,S,E,B,D)
Current status of globin gene therapy for the treatment of beta-thalassaemia.
[My paper] Leszek Lisowski, Michel Sadelain
Memorial Sloan-Kettering Cancer Center, and Weill Graduate School of Mediccal Sciences, Cornell University, New York, NY 10021, USA.
beta-Thalassaemia major is a congenital anaemia for which there is presently no curative therapy other than allogeneic haematopoietic stem cell transplantation. This therapeutic option, however, is not available to most subjects for whom there is no available human leucocyte antigen-matched bone marrow donor. The transfer of a regulated globin gene in autologous haematopoietic stem cells is therefore a directly needed alternative treatment. This strategy, simple in principle, raises major challenges in terms of controlling transgene expression, which ideally should be erythroid-specific, differentiation- and stage-restricted, elevated, position independent, and sustained over time. Using lentiviral vectors, it has been demonstrated that an optimized combination of proximal and distal transcriptional control elements permits lineage-specific and elevated beta-globin expression in vivo, resulting in the correction of anaemia and secondary organ damage in beta-thalassaemic mice. Several groups have extended these findings to various models of beta-thalassaemia and sickle cell disease. Different globin vectors, however, do not express beta-globin at the same level, and accordingly require the delivery of markedly different vector copy numbers to correct anaemia. Insulators are under investigation to assess whether they might enhance globin gene expression or vector safety. Altogether, recent advances in globin vector design bode well for upcoming clinical trials to assess the therapeutic value of globin gene transfer.

Slow progress is being made with a focus being made on controlling the procedure to produce consistent results.


All we are saying is give thals a chance.
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!